Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma
A panel of experts on multiple myeloma discuss dermatologic adverse effects seen in patients receiving talquetamab, including nail toxicities.
This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
Talquetamab-induced dermatologic toxicities like rash (73% incidence) and palm/sole exfoliation arise early, mostly self-resolve within about a month, and infrequently prompt dose reductions (9%,≤2% discontinuations). Nail changes in 55% manifest later around 2 months. Although lasting throughout talquetamab therapy, nail toxicities are mostly aesthetic and rarely dose limiting (1% reductions, no discontinuations). Supportive measures for rash include barrier/moisturizing creams; antihistamines; topical/systemic steroids; and patient education on skin care, preventing infections, and prompt reporting of problems. For nail changes, nail hardeners, topical vitamin E, antibiotic ointments, nail trimming, moisture maintenance, avoiding tight shoes, hand sanitizer moderation, and moisturizing may help. Although they are mostly low grade, recognizing and quickly managing dermatologic adverse events is key.
Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
